AKT1 and prostate cancer: Forty common targets are mainly distributed in PI3K-Akt, MAPK, AGE-RAGE, HIF-1, estrogens, and other signaling pathways, which suggests that XHP can treat prostate cancer by acting on multiple signaling pathways.